These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 234033)
1. Immunochemotherapy of transplantable Moloney leukemia with cyclophosphamide and allogeneic spleen lymphocytes and reversal of graft-versus-host disease with alloantiserum. Kende M; Keys LD; Gaston M; Goldin A Cancer Res; 1975 Feb; 35(2):346-51. PubMed ID: 234033 [TBL] [Abstract][Full Text] [Related]
2. Further development of a successful protocol of graft versus leukemia without fatal graft-versus-host disease in AKR mice. Chester SJ; Esparza AR; Flinton LJ; Simon JD; Kelley RJ; Albala MM Cancer Res; 1977 Oct; 37(10):3494-6. PubMed ID: 20223 [TBL] [Abstract][Full Text] [Related]
3. Graft versus leukemia without fatal graft-versus-host disease in AKR mice. Chester SJ; Esparza AR; Albala MM Cancer Res; 1975 Mar; 35(3):637-9. PubMed ID: 234789 [TBL] [Abstract][Full Text] [Related]
4. Adoptive therapy of established syngeneic leukemia by cells primarily sensitized in vitro. Cheever MA; Greenberg PD; Fefer A Cancer Res; 1981 Jul; 41(7):2658-63. PubMed ID: 7018668 [TBL] [Abstract][Full Text] [Related]
5. Treatment of an established graft-versus-host reaction in AKR mice by adoptive immunotherapy. Chester SJ; Esparza AR; Albala MM Cancer Res; 1975 Mar; 35(3):634-6. PubMed ID: 234788 [TBL] [Abstract][Full Text] [Related]
6. Treatment of a Moloney lymphoma with cyclophosphamide and H-2-incompatible spleen cells. Fefer A Cancer Res; 1973 Apr; 33(4):641-4. PubMed ID: 4696464 [No Abstract] [Full Text] [Related]
7. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Johnson BD; Drobyski WR; Truitt RL Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480 [TBL] [Abstract][Full Text] [Related]
8. Treatment of Moloney virus-induced leukemia with cyclophosphamide and specifically sensitized allogeneic cells. Glynn JP; Kende M Cancer Res; 1971 Oct; 31(10):1383-8. PubMed ID: 5095130 [No Abstract] [Full Text] [Related]
9. The allogeneic effect on tumor growth. II. Suppression of both ascitic and solid MOPC 315 plasmacytoma by the graft-vs-host reaction, with pathologic correlation. Osborne DP; Katz DH J Immunol; 1977 Apr; 118(4):1449-55. PubMed ID: 15035 [TBL] [Abstract][Full Text] [Related]
10. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens. Cohen P; Vourka-Karussis U; Weiss L; Slavin S J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438 [TBL] [Abstract][Full Text] [Related]
11. Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease. Yang I; Weiss L; Abdul-Hai A; Kasir J; Reich S; Slavin S Cancer Res; 2005 Nov; 65(21):9735-40. PubMed ID: 16266994 [TBL] [Abstract][Full Text] [Related]
12. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice]. Li Y; Guo K; Chen Y; Song Z; Li J; Deng L Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):411-4. PubMed ID: 12411044 [TBL] [Abstract][Full Text] [Related]
13. Graft-vs-leukemia and moderation of graft-vs-host reaction in transplantation therapy of viral leukemia. Okunewick JP; Meredith RF; Raikow RB; Brozovich BJ; Magliere K Exp Hematol; 1981 Aug; 9(7):754-65. PubMed ID: 7032959 [TBL] [Abstract][Full Text] [Related]
14. Effect of cyclosporine A and methylprednisolone on the graft-versus-leukemia effects across major histocompatibility barriers in mice following allogeneic bone marrow transplantation. Weiss L; Reich S; Slavin S Bone Marrow Transplant; 1990 Oct; 6(4):229-33. PubMed ID: 2085696 [TBL] [Abstract][Full Text] [Related]
15. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation. Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447 [TBL] [Abstract][Full Text] [Related]
16. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments. Weiss L; Reich S; Slavin S Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572 [TBL] [Abstract][Full Text] [Related]
17. Graft versus leukemia. VIII. Selective reduction in antihost reactivity without loss of antileukemic reactivity by treatment of donor mice with lipopolysaccharide. Truitt RL; Rose WC; Rimm AA; Bortin MM Exp Hematol; 1978 May; 6(5):488-98. PubMed ID: 26584 [TBL] [Abstract][Full Text] [Related]
18. Prevention of lethal graft-versus-host disease in mice by monoclonal antibodies directed against T cells or their subsets. I. Evidence for the induction of a state of tolerance based on suppression. Knulst AC; Tibbe GJ; Noort WA; Bril-Bazuin C; Benner R; Savelkoul HF Bone Marrow Transplant; 1994 Mar; 13(3):293-301. PubMed ID: 8199571 [TBL] [Abstract][Full Text] [Related]
19. Tumor neutralization, immunotherapy, and chemoimmmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro. Cheever MA; Kempf RA; Fefer A J Immunol; 1977 Aug; 119(2):714-8. PubMed ID: 886192 [No Abstract] [Full Text] [Related]
20. Suppression of secondary cellular immunity to a tumor allograft by cyclophosphamide and 1,3-bis(2-chloroethyl)-1-nitrosourea. Einstein AB; Fass L; Fefer A Cancer Res; 1975 Mar; 35(3):492-6. PubMed ID: 1078784 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]